http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2008093855-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate | 2008-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2008093855-A1 |
| titleOfInvention | Composition for treatment of undifferentiated gastric cancer |
| abstract | An object of the present invention is to provide a therapeutic agent, kit and treatment method for undifferentiated gastric cancer, and to be selected from the group consisting of cells overexpressing FGFR2 and cells expressing mutant FGFR2 An object of the present invention is to provide a pharmaceutical composition, a kit, and a treatment method that exert an effect more effectively on a living body including at least one. In the present invention, by using a combination of an FGFR2 inhibitory substance and a gastric cancer therapeutic substance, an effect can be more effectively exhibited against undifferentiated gastric cancer. Further, by using a combination of a FGFR2 inhibitor and a gastric cancer therapeutic substance, a living body comprising at least one selected from the group consisting of cells overexpressing FGFR2 and cells expressing mutant FGFR2 Thus, the effect can be exhibited more effectively. Formula (I) |
| priorityDate | 2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 281.